This Stellar Vanguard ETF Is Beating the VTI and VOO This Year
Key Points The VOO and VTI are exceptional Vanguard ETFs, but the VGK is a worthy complement, especially for investors who want more of a value tilt. Diversifying internationally may be viewed as overrated for some. But amid climbing multiples in U.S. stocks, I think the case for expanding internationally is strengthening. It’s cheap to […]
Abbott: GLP-1 Beneficiary – A Dividend Raise May Be Coming
Surgery beats Ozempic for long-term health, Cleveland Clinic finds
Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.
Prevent Muscle Loss During GLP-1 and Rapid Weight Loss
Trump says Ozempic prices will be ‘much lower’ for Americans – Fox Business
Trump says Ozempic prices will be ‘much lower’ for Americans Fox Business Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs The Wall Street Journal Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s CNBC GLP-1 stocks wilt following Trump comments Axios Trump’s Ozempic comment that sent weight […]
GLP‐1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study
Abstract Aims Evidence on the safety of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RA) concerning non-arteritic anterior ischemic optic neuropathy (NAION) is inconclusive, with several studies published to date presenting methodological challenges. We sought to compare the risk of presumed NAION in patients with type 2 diabetes (T2D), initiating a GLP-1RA versus a sodium-glucose […]
Effects of GLP‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized controlled trials
Abstract Aims Patients with type 2 diabetes mellitus (T2DM) have a significantly increased risk of cognitive impairment, and the protective effects of traditional hypoglycaemic drugs on cognitive function remain unclear. This study systematically evaluated the neuroprotective effects of GLP-1 receptor agonists (GLP-1RAs) based on randomized controlled trial (RCT) evidence, aiming to provide key evidence-based insights […]
Can Ozempic help you cut back on alcohol? Researchers think so
Semaglutide, tirzepatide, and other GLP-1 drugs appear to slow alcohol absorption and blunt its intoxicating effects, according to new research. The study found participants on these medications felt less drunk despite consuming the same amount of alcohol. This could point to a safer, faster-acting way to help people reduce drinking—distinct from traditional treatments that target […]
FDA Approves Novo Nordisk’s Rybelsus Diabetes Pill to Reduce Heart Risk
Novo Nordisk(NVO) announced that the U.S. FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events such as cardiovascular death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they’ve had a prior CV event or […]
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best healthcare stocks with the highest upside. Viking Therapeutics, Inc. (NASDAQ:VKTX) received a Buy rating from Oppenheimer’s Jay Olson on October 7, who assigned a $100 price target to the stock’s shares. H.C. Wainwright analyst Joseph Pantginis also reiterated a bullish stance on Viking Therapeutics, Inc. (NASDAQ:VKTX) […]